T 0412/93 (Erythropoietin/KIRIN-AMGEN) of 21.11.1994
- European Case Law Identifier
- ECLI:EP:BA:1994:T041293.19941121
- Date of decision
- 21 November 1994
- Case number
- T 0412/93
- Petition for review of
- -
- Application number
- 84308654.7
- IPC class
- C12N 15/00
- Language of proceedings
- English
- Distribution
- Distributed to board chairmen and members (B)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- Production of erythropoietin
- Applicant name
- Kirin-Amgen, Inc.
- Opponent name
- Genzyme Corporation
Elanex Pharmaceuticals Inc.
Merckle GmbH Chem.-pharm. Fabrik
Boehringer Mannheim GmbH Patentabteilung
Behringwerke Aktiengesellschaft
Akzo Pharma B.V. - Board
- 3.3.04
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 123 1973European Patent Convention Art 54 1973European Patent Convention Art 56 1973European Patent Convention Art 83 1973European Patent Convention Art 84 1973European Patent Convention R 28 1973
- Keywords
- Circumstances where novelty of product by process features can be acknowledged
Sufficiency of disclosure of a dependent claim - no
Deposit not required by Rule 28 and Article 83 EPC to make something already possible easier; no best mode requirement under the EPC
Inventive step - yes
Novelty - product by process features - Catchword
- -
ORDER
For these reasons it is decided that:
1. The decision under appeal is set aside.
2. The case is remitted to the first instance with the order to maintain the patent on the basis of Claims 1 to 31. of the eleventh auxiliary request submitted on 22. September during the oral proceedings.